SCHEMBL483300

SCHEMBL483300

CCC#Cc1[c]cccc1

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.32
KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613219 0.84 KCNH2 (0.39) KCNH2
SCHEMBL613452 0.81 KCNH2 (0.47) KDM4ELMNAKCNH2
SCHEMBL2649459 0.81 ALDH1A1 (0.36) KDM4ELMNA
SCHEMBL2650824 0.79 CYP2A6 (0.41) LMNA
SCHEMBL8114609 0.78 KCNH2 (0.57) KDM4EKCNH2
SCHEMBL8113698 0.78 KCNH2 (0.57) KDM4EKCNH2
SCHEMBL6295153 0.78 FFAR1 (0.38) KCNH2
SCHEMBL483062 0.76
SCHEMBL3300725 0.73 HTR2A (0.34)
SCHEMBL2116025 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 EP claimed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 EP claimed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 WO claimed
EP-3045219-B1 METHOD FOR REMOVING SOX FROM GAS USING MODIFIED POLYETHYLENE GLYCOL BEIJING BOYUAN HENGSHENG HIGH TECH CO LTD (CN) 2023-10-04 EP disclosed
CN-110446739-B Fluoroacetophenone-containing derivative, fluorine-containing additive, curable composition containing the same, and cured product thereof DIC株式会社 2022-01-11 CN disclosed
US-10961405-B2 Fluorine-containing acetophenone derivative, fluroine based additive, curable composition including same, and cured product thereof DIC CORPORATION (JP) 2021-03-30 US disclosed
CN-111954849-A Photosensitive resin composition, cured product, insulating material, resin material for solder resist, and resist member DIC株式会社 2020-11-17 CN disclosed
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 US disclosed
WO-2019198489-A1 PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT, INSULATING MATERIAL, RESIN MATERIAL FOR SOLDER RESISTS AND RESIST MEMBER DIC株式会社 2019-10-17 WO disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 US disclosed
EP-0860741-A1 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1998-08-26 EP disclosed
US-5721288-A FOR UNSATURATED COMPOUNDS FUJI PHOTO FILM CO., LTD. (JP) 1998-02-24 US disclosed
EP-0822447-A1 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1998-02-04 EP disclosed
US-5703140-A CONTAINS ETHYLENICALLY UNSATURATED BOND, OXIME ETHER COMPOUND, SPECTRAL SENSITIZING DYE FUJI PHOTO FILM CO., LTD. (JP) 1997-12-30 US disclosed
EP-0726497-A2 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1996-08-14 EP disclosed
EP-0726498-A1 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1996-08-14 EP disclosed
EP-0724197-A1 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1996-07-31 EP disclosed
US-5491167-A INHIBITORS OF CHOLESTEROL BIOSYNTHESIS SANKYO COMPANY, LIMITED (JP) 1996-02-13 US disclosed
EP-0609058-A2 Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1994-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 KDM4E 4412/4885LMNA 2990/4885NPSR1 176/4885
US-10239829-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 KDM4E 4337/4885LMNA 2663/4885NPSR1 192/4885
US-10807946-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 KDM4E 4338/4885LMNA 2621/4885NPSR1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.